Sana Biotechnology Reports Sustained Positive 14-Month Results from Type 1 Diabetes Islet Cell Transplant Study Without Immunosuppression
Sana Biotechnology reported continued positive clinical results from its cell therapy programs, reinforcing its broader strategy of developing engineered cells as medicines. The update primarily focused on early-stage clinical trials evaluating hypoimmune (HIP) cell technologies, which are designed to evade immune rejection without the need for long-term immunosuppression.
The company highlighted progress in patients treated with engineered pancreatic islet cells for diabetes. These cells are modified to avoid immune detection...
